PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10296146

Drug interaction microcomputer software evaluation: Therapeutic Software's Adverse Interactions.

T I Poirier·R A Giudici
View original source ↗Export metadata ↓

Abstract

Therapeutic Software's Adverse Interactions was evaluated using general and specific criteria. The installation process, ease of learning, and technical support were rated as excellent. The ease of use and documentation for use were rated as good. The program received an excellent rating for the quality of the clinical documentation and good ratings for the scope of coverage and overall clinical performance. The frequency of updates is fair. The program is an excellent value because of its comprehensiveness, sources of the data base, and relatively low cost. It may be one of the better buys for drug interaction softwares.

Explore related subjects

Drug InteractionsDrug Therapy, Computer-AssistedEvaluation Studies as TopicSoftwareStatistics as TopicTherapy, Computer-AssistedJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T I Poirier, R A Giudici. 1989. Drug interaction microcomputer software evaluation: Therapeutic Software's Adverse Interactions.. https://pubmed.ncbi.nlm.nih.gov/10296146/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Interaction of taxol with human serum albumin.

Taxol (paclitaxel) is an anticancer drug, which interacts with microtuble proteins, in a manner that catalyzes their formation from tubulin and stabilizes the resulting structures (Nogales et al., Nature 375 (1995) 424-427). This study was designed to examine the interaction of taxol with human serum albumin (HSA) in aqueous solution at physiological pH with drug concentrations of 0.0001-0.1 mM, and HSA (fatty acid free) concentration of 2% w/v. Gel electrophoresis, absorption spectra and Fourier transform infrared (FTIR) spectroscopy with self-deconvolution and second-derivative resolution enhancement were used to determine the drug binding mode, binding constant and the protein secondary structure in the presence of taxol in aqueous solution. Spectroscopic evidence showed that taxol-protein interaction results into two types of drug-HSA complexes with overall binding constant of K=1.43 x 10(4) M(-1). The molar ratios of complexes were of taxol/HSA 30/1 (30 mM taxol) and 90/1 (90 mM taxol) with the complex ratios of 1.9 and 3.4 drug molecules per HSA molecule, respectively. The taxol binding results in major protein secondary structural changes from that of the alpha-helix 55 to 45% and beta-sheet 22 to 26%, beta-anti 12 to 15% and turn 11 to 16%, in the taxol-HSA complexes. The observed spectral changes indicate a partial unfolding of the protein structure, in the presence of taxol in aqueous solution.

Drug Interactions↗